Current Pipeline
COMPOUND (TARGET)
INDICATION(S)
DISCOVERY
IND ENABLING
PHASE I
PHASE II
PHASE III
NS-041
(KCNQ2/3 activator)
Focal onset seizure
Major depressive disorder
Pain
NS-136
(mAChR4 PAM)
Schizophrenia
Psychosis in Alzheimer's disease
NS-079
(Neuroplasticity)
NS-031
(NMDAR)
NS-050
(Neuroinflammation)
Treatment-resistant depression
Treatment-resistant depression
Alzheimer's disease
Parkinson’s disease
Clinical Trials
COMPOUND
INDICATION
STAGE
STUDY DESCRIPTION
STATUS
NS-041
Focal onset seizure
Phase II
A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of NS-041 as an adjunct treatment for focal onset seizure
View StudyRecruiting
NS-136
Schizophrenia
Phase IIa
A phase IIa, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of NS-136 for the treatment of schizophrenia
View StudyInitializing
Publications
